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Arsenite as the Probable Active Species
in the Human Carcinogenicity of Arsenic:
Mouse Micronucleus Assays on Na and K
Arsenite, Orpiment, and Fowler's
Solution
by H. Tinwell,* S. C. Stephens,t and J. Ashby*
Sodiumarsenite, potassiumarsenite, andFowler's solution (arsenictrioxidedissolvedinpotassium bicarbonate) are
equallyactiveinthemousebonemarrowmicronucleus assay( 1 10mg/kgbyIPijection). Thenaturaloreorpment(prin-
cipally AS2S3) wasinactive despite blood levels ofarsenic of300 to900ng/mLintreatedmiceat24hr. Sodiumarsenite
wasactive inthreestrainsofmice. Itissuggestedthatthehumanlungcancerobserved amongarsenicoresmeltersand
theskincanceramongpeopleexposedtherapeutically toFowler'ssolution, have, astheircommonorigin, thegenotoxic
arsenite ionAsO;-. Thedifficultyexperiencedwhenattemptingtodemonstraterodentcarcinogenicityforderivativesof
arsenicsuggeststhatthebonemarrowmicronucleus assay mayactasausefulassayforpotentiallycarcinogenicarsenic
derivatives.
Introduction
Attention has recently been focused ontheclastogenic activity
ofmostofthe human carcinogens (including arsenic) tothe ro-
dent bone marrow (1,2). TheInternational Agency for Research
on Cancer (IARC) (3,4) hasclassifiedarsenic anditsderivatives
as having sufficient evidence for carcinogenicity in man and
limited evidence in animals, but the active species is not clear.
Shelby (1)quotedthepositive mousebone marrowmicronucleus
assay datareported forsodiumarseniteby Deknudtetal. (5), but
an earlier negative bone marrow cytogenetic study on arsenic
trioxide alsoexists (6). Giventhe rangeofarsenic derivatives to
which manhasbeenexposedandtheuncertainty surroundingthe
active carcinogenic species (7), we decided to conduct mouse
bone marrow micronucleus assays on a range ofderivatives of
arsenic.
There aretwomajorassociationsbetweenhuman cancerand
exposuretoderivativesofarsenic: lung canceramongarsenic ore
smelters and skin cancer among peopleexposed therapeutical-
ly to Fowler's solution (potassium arsenite). Arsenic occurs in
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nature mainly in combination with sulfur, the main oresbeing
arsenic trisulfide (orpiment, As2S3), arsenicdisulfide (redorpi-
mentorrealgar, As4S4), andarsenopyrite(FeAsS). Italsooccurs
intheseformsandasarsenides(e.g., niccolite, NiAs)asanim-
purity(upto3%)inmanynonferrousoressuchasinthoseofzinc
and copper.
Natural weatheringofsulfideorescanleadtonaturaldeposits
ofoxidesofarsenic. Orpiment(As2S3)wasmentionedbyAristo-
tieandwasbeingroastedtoyieldarsenictrioxide(whitearsenic;
As203) asearly asthefirstcenturyA.D. (8). However, apartfrom
the roasting ofFeAsS inJapan, the specific roasting ofarsenic
ores is not nowcommerciallypracticed. Rather, the incidental
roastingofarsenicoresduringthesmeltingofothernonferrous
oresprovidesthemajorsourceofarsenic asarsenictrioxidetrap-
pedinflues. Themainincidences ofhumancancerappeartobe
associatedwiththecullingandfurtherpurificationoftheseflue
deposits.
Fowler's solutionispreparedbydissolving As203inaqueous
potassium bicarbonate and is formally aqueous potassium
arsenite. Itsmedicinalusewasmainlyforthetreatmentofarange
ofskinconditions, butitisnolongerusedtherapeutically. There
isthereforeapossiblelinkbetweenthehumanlungcancerinduc-
edbytherefiningofAs203andtheskincancerinducedbytheap-
plicationofpotassiumarsenite, whichispreparedfromAs203.
Wethereforedecidedtorepeatthepositivemousebonemarrow
micronucleus assay of Deknudt et al. (5) on sodium arseniteTINWELL ETAL.
along with assays onpotassiumarsenite, Fowler's solution, and
orpiment. selecteddeterminations were madeofbloodlevelsof
arsenic in treated animals in order to relate genetic activity to
bioavailability ofarsenic.
Materials and Methods
Nomenclature ofArsenic andIts Derivatives
Arsenic was known to the ancient Greeks in the form ofthe
poisonousgold/red-coloredsulfideore(Zarnig, Iranianforgold;
arrhen, Greek for virile, thus, arsenikon for the gold-hued
poison, As2S3, the Latinauripigmentum led to the nameorpi-
ment). Thereisthepotential forconfusionwiththeterminology
appliedtoarsenites. Inchemistry bookswrittenattheturnofthe
century (9), arsenious acid is given as As(OH)3, thus, sodium
arsenite is Na2AsO3. Adehydratedacidisalsodescribedasmeta-
arsenious acidAs(O)OH, whose sodium salt wouldbe sodium
meta-arsenite, NaAsO2. These separateterminologies are still
used, buttheseparateexistenceofarsenites andmeta-arsenites
isno longerconsideredvalid. Thus, the 11theditionoftheMerck
Index (10) lists sodium meta-arsenite as an alternative name to
sodiumarsenite, providinganapproximate structureofNaAsO2.
Potassium arsenite is listed as being KAsO2:HAsO2 and the
meta-arsenite is not mentioned. Likewise, the Merck Index
names KAsO2 as the product formed from As203 in Fowler's
solution, i.e., potassiumarsenite. Confirming thisconfusion of
terms, Scheele's green, copper hydrogen arsenite, is given by
Merck inbothoftheaboveforms: CuHAsO3 andCu(AsO2). In
thispaperthenamesandmolecularspecies usedaresodiumar-
senite(NaAsO2), potassiumarsenite(KAsO2:HAsO2), arsenious
trioxide (As203), Fowler's solution (regarded as potassium
arsenite), andorpiment (As2S3). Inthefinalexperiment(Experi-
ment8 inTable 1)alldosedanimals receivedequimolararsenic,
independent ofthe chemical species under test.
Chemicals
Cyclophosphamide (CP) was purchased from the Sigma
Chemical Company (Poole, Dorset, U.K.), sodium and potas-
siumarsenite wereobtained from BDH Chemicals Ltd.(Poole,
Dorset, U.K.). Fowler's solution was prepared by dissolving
As203 (Ventron, Alfa, Coventry, U.K.) (1 g) in water (50 mL)
and a solution ofpotassium bicarbonate (0.76 g) in water (50
mL). Ethanol wasaddedtoproducea3% solution. Asampleof
this solution (760jtL) wasaddedtowater(10mL) forthedosing
solution (10 mL/kg gave equimolar arsenic to NaAsO2 [10
mg/kg]). Orpiment was purchased from a mineral shop in
Brussels, butthe address was not noted and its location cannot
be found. The sample used was bright yellow with red streaks
andmetallicveins. TheyellowregionsareAs2S3, andtheorange-
coloredonesarerealgar(As2S4). Leavesofarsenicmetalcould
be seen by their ability to reflect light. Inductively coupled
plasmaemissionspectrometry revealedacompositionofapprox-
imately 61.6% arsenic, 38.5% sulfur, and 0.5% antimony
(theoretical values for As2S3 are 61.0% As and 39.0% S). The
mineral wasfriableandwasgroundtoafinepowderusingapes-
tleand mortar. Thefragmentsofmetallicarsenic wereremoved.
Theyellowpowderwasaddedtocornoil (experiment 1). Inex-
periments2, 6, and7, thecornoil suspension wasball-milledfor
either 24 hr (experiment 2) or 72 hr (experiments 6 and 7;
Table 1). Finally, the suspensions were homogenized using an
ultra-Turraxhomogenizer(11)for0.5 hrimmediatelybeforedos-
ing. In the arsenic determinations, the following reagents were
used: nickel nitratehexahydrate, analargrade(BDHChemicals,
Ltd.) Triton X-100 (BDH Chemicals Ltd.), arsenic stock solu-
tion, 1000/Lg/mL, spectrosol grade (BDH Chemicals Ltd.).
Animals andDosing
MaleCBA/CafAP/Alpkmice(experiments 1, 2, 5, 6, and7),
maleBALB/cfBLIO/Alpkmice(experiments 3 and4) andmale
C57BL/6JfBL1O/Alpk mice (experiment 8) age 8 to 12 weeks
were used. Animals were housed and maintained as described
previously (12) and were allowed Porton diet and water ad
libitum. With the exception ofexperiment 1, each animal re-
ceived asingleoral orIPdose (10mL/kg oras stated below) of
thetestchemical24hrbeforesacrifice. Animalsusedinexperi-
ment 1 receivedthreedailyoralgavagesofthetestcompounds,
andthebonemarrowwassampled24hrafterthefinaldose. The
dose-level oforpiment(experiments2,6, 7) wasdeterminedby
estimating the amountofmaterial remaining fromtheoriginal
amount ball-milled, i.e., the suspension was removed and its
volume measured and any remaining solid determined gravi-
metricallyafterwashingwithacetoneanddrying. Adjustments
to thedosingvolume were then made togive a maximum dose
of 500 mg/kg orpiment. To ease dosing, orpiment was ad-
ministered using adosing volume of20mL/kg body weight in
experiments2, 6, and7, aswascornoilinexperiment7. Thedose
levelof500mg/kgsuspensionusedinexperiment7(Table 1)was
analyzed forarsenic (seebelow) andfoundtobewithin95% of
theory (i.e., 1.2% arsenic). Initialdoselevelsofsodiumarsenite
(usedasapositivecontrol) werebasedonliteraturevalues (5).
However, itsinitialinactivity inthemousebonemarrow(experi-
ment2) ledtoamorein-depthevaluationofitsmaximumlethal
dose(MLD)andoptimumrouteandvehicle(experiments 3, 4,
and5). AcombinationofasingleIPinjectionof10mg/kg(80%
4-dayMLD)sodiumarsenitedissolvedindistilledwatergaveop-
timumresults (experiments 4and5). CPwasusedatadoselevel
previously used in this laboratory (13).
Micronucleus Assays
Bonemarrow smearswerepreparedasdescribedpreviously
(14) with a minor alteration. Briefly, the femoral cells were
flushed out with fetal calf serum (FCS; Northumbria Bio-
logicals, Northumberland, U. K.) containing 25 mM EDTA,
resuspendedandfilteredthroughboltingcloth (150,m; Henry
Simon Ltd., Stockport, U.K.). Afterspinning (2000rpmfor5
min), the resultant marrow button was resuspended in a small
volumeofsupernatant, and smears werepreparedbyplacing a
drop ofthis suspension onto the center ofa methanol-cleaned
slide. A second slideplaced on topofthe first spread thisdrop
by capilliary action. The two resulting smears were then slid
apart, air dried, and fixed in methanol for 5 min. These were
stainedwithacridine orangeasdescribedpreviously(14). Atotal
of2000polychromaticerythrcytes(PE)peranimalwerescored
formicronucleatedPE(MPE). Theerythropoieticratio(poly-
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Table 1. Results ofeight experiments to evaluate and compare the micronucleus-inducingability ofderivatives ofarsenic.a
MPE/1000 PE As/mL ofcombined
Experiment No. of Group mean blood from test
no. Compound Dose, mg/kg/route animals Individual animal data ± SD PE/NE ± SD group, ng/mL
Experiment I Corn oil 10 mL/oral 6 0.5, 2, 4, 1, 1, 3 1.9 ± 1.4 1.1 + 0.2 ND
3 daily doses, Orpiment 100/oral 6 2, 1.5, 2.5, 2.5, 1.5, 1.5 1.9 ± 0.5 0.9 ± 0.1 ND
CBA mice Cyclophosphamide 10/oral 3 36.5, 18, 36 30.1 ± 10.5' 0.4 + 0.2' ND
Experiment 2 Cornoil 10 mL/oral 5 1.5,2.5,0.5, 1.5, 2.5 1.7 ± 0.8 0.9 ±0.1 < 100
I dose, Corn oil 10 mL/IP 5 1, 0.5, 2,0.5,0.5 0.9 ±0.65 1.0 + 0.1 < 100
CBAmice Naarsenite 10/IP 5 1.5, 1.5, 1, 1, 2.5 1.5 + 0.6 1.0 ± 0.1 < 100
Na arsenite 5/IP 5 3.5, 1.5, 2, 3, 1 2.2 + 1.0 1.0 + 0.1 < 100
Na arsenite 2.5/IP 5 3, 2, 1, 3.5, 2 2.3 ± 1.0 1.1 ± 0.03 < 100
Orpiment 500/oral 5 0.5,2.5,2.5, 1, 1.5 1.6 ± 0.9 1.0 + 0.1 900
Experiment 3
1 dose, Na arsenite 5/IP 3 7.5, 9, 8 8.2 ± 0.8 0.9 ± 0.1 ND
BALB/c mice (in water)
Experiment 4 Distilled water 10 mL/IP 4 3, 3.5, 3.5, 2.5 3.1 ± 0.5 1.1 ± 0.2 ND
I dose, Naarsenite 5/IP 5 8,4.5,4,4.5 5.25 ± 1.8* 1.1 ± 0.1 ND
BALB/c mice (in water) 10/IP 5 4, 7, 5, 8.5, 5 5.9 ± 1.8* 0.95 ± 0.2 ND
Cornoil 10 mL/IP 5 1, 1,2.5, 2.5, 1.5 1.7 ±0.8 1.15 + 0.15 ND
Naarsenite 10/IP 5 2, 4, 2.5,1,1.5 2.2 ± 1.15 1.1 ± 0.1 ND
Experiment S Distilled water 10 mL/IP 6 3, 3, 2, 5, 2.5, 1 2.75 + 1.3 1.0 + 0.1 ND
1 dose, Naarsenite 10/IP 6 14, 13, 9.5, 11, 13.5, 7.5 11.4 ±2.6k 0.5 +0.1 ND
CBA mice (in water)
Experiment6 Cornoil 10mL/oral 6 2, 2,2,1.5,2,1 1.75 ±0.4 1.1 ±0.1 < 100
I dose, Orpimente 160/oral 6 4, 5, 3, 4.5, 3, 2 3.6 ± .lt 1 ± 0.1 390
CBA mice Naarsenite 10/IP 6 9.5, 6.5, 9, 8, 9, 10 8.7 + 1.25t 0.6 ± 0.01 < 100
(in water)
Experiment 7 Cornoil 20 mL/oral 5 3.5, 3, 3.5, 2, 2.5 2.9 ± 0.65 1.0 + 0.2 < 100
1 dose, Orpiment 500/oral 5 5, 5, 4.5, 3, 2.5 4 + 1.2 0.8 + 0.1* 650
CBA mice Na arsenite 10/IP 5 3,2.5, 1.5, 1, 2.5 2.1 + 0.8 1.1 + 0.2 < 100
Naarsenite 10/IP 5 8.5, 5, 11, 4.5, 12.5 8.3 ± 3.S5 0.7 + 0.1* < 100
(in water)
Experiment 8 Distilled water 10 mL/IP 5 1.5, 3, 3.5, 2.5, 4.5 3.0 ± 1.1 0.95 + 0.1 ND
1 dose, (3% EtOH)
C57BL6 mice Na arsenitec 10/IP 5 8.5, 15.5, 25, 27.5, 11.5 17.6 + 8.3' 0.6 ± 0.2t ND
(in water)
K arsenite 9.8/IP 5 11, 19.5, 15, 14.5, 9.5 13.9 3.9t 0.85 ± 0.2 ND
(in water)
Fowler's solutionc 7.6/IP 5 10, 15, 13.5, 12, 8.5 11.8 + 2.6t 1.0 ± 0.1 ND
(expressed as As203)
Cyclophosphamide 65/IP 3 58.5, 75.5, 89.5 74.5 ± l5.5t 0.9 + 0.03 ND
(in water)
'Unless stated otherwise, test agents were dosed in corn oil; water refers to solution in distilled water. MPE, micronucleated polychromatic erythrocytes; PE,
polychromatic erythrocytes; NE, normochromatic erythrocytes. MPE/1000 PEbased on 2000 PE peranimal.
b500 mg/kg intended, less suspended than expected.
cEach formulationdelivering equimolar arsenic as As; 5.76 mg/kg; results statistically insignificant from each otherusing two-tailed Student's t-test.
*p < 0.05, one-tailed Student's t-test.
tp < 0.01, one-tailed Student's t-test.
chromatic/normochromatic [PE/NE]), was determined among
1000erythrocytes (PE and NE).
Determination ofArsenic in Blood
Amethod wasdeveloped todeterminearsenic inmouseblood
by electrothermal atomicabsorption spectroscopy (ETA-AAS).
Typical samplepreparationprocedures involvedigestionofthe
bloodwithacids (15); however, thesemethodsaretimeconsum-
ing and risk contamination. A simple, rapid method has been
developedthatinvolvesdilutingthebloodwithdeionizedwater
andTritonX-100. Thedirectinjectionofbloodintothegraphite
furnace results in a buildup ofcarbonaceous residue and non-
specificabsorptionduringtheatomizationcycle, andprecautions
mustbetakentoefficientlyashthesamplewithoutthevolatiliza-
tionofarsenic. Thechemicalstabilizationofarsenic wasachiev-
edusingnickelnitrateasamatrixmodifier(16). However, ithas
been found that the addition ofNi to blood results in coagula-
tion/precipitation of proteins (17), therefore a "within-tube"
standards-addition procedure was usedby addingthe As stan-
dardandNitothesamplebeforethedry/ash/atomization cycle.
AL'Vovplatform was used(18). The introduction ofoxygendur-
ing the ash stage was evaluated and rejected (19-21).
Instrumentation
APerkinElmermodel3030atomicabsorptionspectrometer
equipped with an HGA-500 graphite furnace and an AS-40
autosampler wereused. Deuterium arcbackground correction
wasused. Absorbance measurements wereat 193.7 nmusingan
argonhollowcathodelamp(PerkinElmer)andabandwidthof
0.7 nm. Pyrolytically coatedgraphitetubeswithtotallypyrolytic
L'Vov platforms were used, and measurements were based on
peakheight, using a readtime of2.0 sec. Someblood samples
contained lumps and these were dispersed using an ultrasonic
processor, modelW-370(HeatSystemsUltrasonic Inc., Farm-
ingdale, New York) in two 10-sec sessions.
Sample Preparation
Blood samplesfromeachtestgroupwerepooledanddiluted
1:4bypipetting500Ztgofbloodanddilutingwith5001ALof0.5%
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Table2. Furnace program.
Phase Temperature, °C Ramp Time/sec
Dry 90 1 30 (300 mL/min Ar)
130 1 30
Ash 1150 5 60 (300 mL/min Ar)
Atomize 2450 0 3 (OmL/min Ar)
Clean 2600 1 1 (300 mL/min Ar)
m/VTritonX-100and 1 mLofdeionizedwaterin30mLSterilin
Universal plastic containers. Blood samples taken from mice
treated with orpiment required a further 10 to 20x dilution.
Arsenic Assays
The Perkin Elmer AS-40 autosampler was used to perform
standard additions to theblood within the atomizer tube. A 10
1zLvolumeofblood wasdispensed ontothe L'Vovplatform in
thegraphitetube, thecapillary wasautomatically washed, and
10AtL ofthe As standard containing 0.2% m/V nickel nitrate
wasdepositedontothedropletofblood (21). Todeterminethe
As content ofthe blood samples, matrix-matched calibration
graphs were prepared using a 1:4 dilution ofblood from mice
treated withcornoil. Thebloodfrommicetreatedwithorpiment
contained higher levelsofAsand wasdiluted toachieve anab-
sorbanceof0.1 to0.2. Astandard-additionsprocedure wasused
tocalculatetheAsconcentration intheblood. Thefurnacepro-
gram is shown in Table 2.
OptimumAssay Conditions
A two-stage temperature program was required to dry the
sampleandtopreventboilingandsputteringoftheblood inthe
graphite tube. Ash/atomization curves for 1.5 ng As in a 1:4
dilutionofbloodusinganArashrevealedthatadditionofnickel
nitrate allowed ash temperatures ofup to 1200°C without the
volatilizationofarsenic. Increasingtheashtime from30secto
60 sec improved the analyte peak shape and assay sensitivity.
Theconcentration ofnickel nitrate wasoptimized. A standard-
additions graph wasprepared in a 1:4dilution ofmouseblood
toobserveanyenhancementorsuppressionoftheanalytesignal
compared with aqueous arsenic standards. It became evident
from these graphs that severe suppression ofthe As signal oc-
curs in theblood matrix. Hence, standard additions ormatrix-
matched standards werenecessary todetermineAsintheblood
samples.
Detection Limit Calculations
A theoretical detectionlimit wascalculated forAs inthe 1:4
dilutionofbloodas35ng/g. Amorerealisticdetectionlimitwas
determined by relating an absorbance, which wasjust visible
abovethebaselinenoise, tothespikedbloodarsenic concentra-
tion. This wascalculatedatapproximately 100ng/gandwasus-
ed as the detection limit for the analytical procedure.
Results
The results ofeightmicronucleus experiments, togetherwith
selecteddeterminationsofarsenic inblood, areshowninTable
1 intheorderinwhichthey wereconducted. Thesequenceofex-
periments illustrates the problems that can beset genotoxicity
testing. Inexperiment 1, anegative test response was observed
fororpiment. Therelatively lowdoselevel used was causedby
problemsencounteredwithdosingthesuspension, butwasoff-
setbytheuseofatriple-doseprotocol. Althoughtheexperiment
hadapositivecontrol (CP), wedecidedtorepeattheexperiment
usingthe moreappropriatepositivecontrol, sodiumarsenite(5).
Confident ofapositive response for sodium arsenite, we omit-
ted CP from experiment 2, and this gave completely negative
data. Nonetheless, weestablishedthatorp.imentwasabsorbed,
albeit the level of arsenic in the arsenite-treated animals was
below the level ofdetection ofthe arsenic assay. Inexperiment
3, werepeatedexactlytheexperimentreportedby Deknudtetal.
(IP injection ofan aqueous solution using male BALB/c mice)
(5). The positive responses observed involved changing two
variables atonce, so in experiment4 we established that IP in-
jection of an aqueous solution was critical for a positive test
response (IP injection in corn oil giving negative results). Ex-
periment5 confirmedthatthestrainofmousewasnotimportant,
so inexperiment6 wereverted tomaleCBAanimals. Inexperi-
ment6, weobservedapositive response forsodiumarseniteand
proofagain that orpiment was absorbed into the bloodstream.
Theorpimentdata fromexperiment6waspositivewhenassess-
ed by statistical analysis. However, the magnitude of this
response laywithinthehistoricalcontrolgroupmeanrange, and
nosuchpositiveeffectwasobservedinexperiments 1,2, or7. Ex-
periment7alsoconfirmedthatsodiumarsenite wasonlypositive
following injection in water. The orpiment response in experi-
ment 7 was elevated but was not statistically significant. In ex-
periment 8, sodium and potassium arsenite and Fowler's solu-
tion, each gaveaclearpositive response; useofathird strainof
mouse inthisexperiment(C57BL6)confirmedthatthegenotox-
icity ofarsenite is strain independent.
Fromtheseexperimentsweconcludethatsodiumandpotassium
arseniteareclearlypositiveinthemicronucleusassay. Fowler's
solutiongaveapositiveresponseofthesamemagnitudeasthatof
theequimolararsenites (experiment8). Orpimentwasabsorbed
asevidencedbytheelevatedlevelsofarsenicinthebloodofmice,
butanoverallnegativemicronucleustestresponsewasobserved.
ArseniteisrapidlyeliminatedwhenadministeredbyIPinjection
(- 75% in24hr)(4),thusthefailuretodetectitinbloodat24hr
indicates adifferentpharmacokinetic profile fromthatoforpi-
ment. The elevated blood levels ofarsenic in orpiment-treated
animals, coupledtothelackofadepressioninerythopoiesis (as
seenforarsenite)areconsistentwithagenetically inactiveformof
arsenicbeingpresentinthebloodoforpiment-treatedmice.
Discussion
Theability oftherodentbonemarrowmicronucleus assay to
detectaspositivethelargemajorityoftheestablishedhumancar-
cinogens qualifies it for use in studying human carcinogens
whoseexactcausativeagentisnotknown. Amongtheestablished
carcinogenichumanenvironments, thecausativeagentincancer
inducedbyderivativesofarsenic isprobablytheleastwelldefin-
ed. Smelting of metal arsenides or arsenic sulfide ores, or
purificationofarsenic trioxidederived as abyproductfromthe
smelting ofothernonferrous ores, andtherapeutic exposure to
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Fowler's solution(potassiumarsenite)hasadequateevidenceof
humancarcinogenicity (3,4,7,22). There is, however, onlyvery
limited evidenceforthecarcinogenicityofarsenicderivativesto
experimentalanimals(4). Neitheris itatallclearhowderivatives
ofarseniccouldcausecancer. Theabilityofsomederivativesof
arsenic to form pseudodisulfidebonds(As-S) isresponsiblefor
a rangeofenzymetoxicities, andthisactivity mayalsoleadtothe
limited evidence for genotoxic activity, most of which is
associated with sodium arseniteand itsabilitytotransformcells
anddamagechromosomes(in vitro) (23,24). Theonlypositive
rodentgenotoxicity datareported inthe literatureforderivatives
of arsenic is for sodium arsenite in the mouse bone marrow
micronucleus assay (5).
The present experimentshaveconfirmed thedataofDeknudt
etal. (5) indicatingthatsodiumarseniteisgenotoxictothebone
marrow cells ofmice. Similaractivity was observed forpotas-
sium arsenite, either as the pure chemical or as formed from
As203 in Fowler's solution(Table 1). In contrast, orpiment was
concluded to be inactive in this assay despite blood levels of
arsenic being at least 10-fold higher in orpiment-treated mice
than inthoseexposedtosodiumarsenite. Thesedatasuggestthat
oxygenderivativesofAs(III) (25) areresponsibleforthecancer
induced in humans. Thus, arsenic trioxide (As203), which is
associatedwithlung cancerinsmelters, issolubleinpotassium
bicarbonate toyieldpotassiumarsenite, which, inFowler'ssolu-
tion, induces skin cancerintreatedhumans. Thepossibility ex-
ists thatAs203absorbedin manformsarsenitebyreactionwith
bicarbonate in blood.
The inactivity oforpiment in themicronucleusassay streng-
thens the ideathatthenaturallyoccurring sulfidesofarsenic do
not contribute directly to smelters' lung cancer. Acorollary of
this inactivity isthattherelatively highlevelsofarsenicabsorbed
bythemice was nottransformed intotheappropriateAs(EI) ox-
ide species. Thisobservation isinterestingwithinthe contextof
the closely allied experiments of Arrouijal et al. (26) and
Hildebrand et al. (27) on nickel subsulfide (a-Ni3S2), the
presumedcarcinogenic species innasal cancerinduced among
nickel ore roasters (28). These investigators demonstrated
solubility for a-Ni3S2 in assay medium and located nickel-
containing deposits within cells treated in vitro. This cellular
bioavailability ofnickel wasprobablyresponsibleforArrouijal
etal. (26)alsobeingabletodemonstrate apositivemousebone
marrow micronucleus assay response for nickel subsulfide.
Itisproposedthatarsenite(AsO2) isthecommoncarcinogenic
species in both the lung cancer among smelters and the skin
cancers amongthoseexposed toFowler'ssolution. Thecommon
activity of these separate arsenic derivatives in the mouse
micronucleusassay(experiment8; Table 1)suggeststhatthistest
system may be more effective than animal carcinogenicity
bioassays fordetermining thepotential carcinogenic haiard of
otherderivativesofarsenic. Thegeneralinsensitivityofrodents
tothecarcinogenicityofderivativesofarsenicremainsamystery.
The extentofhuman exposure to arsenic trioxide was substan-
tialinthelastcentury, thesublimationchambersbeingreferred
toasthepoisontower(Fig. 1). Obviously, underthoseconditions
ofexposure, cancerdidnotbecomeapparentduetoearlydeaths,
as evidenced by the following quotation: "Its manufacture
[As203] hasbeenchieflyconfinedtoBohemiaandHungary. Per-
sonsbroughtupfromtheiryouthintheworkslivenotlongerthan
FIGURE 1. Muspratt(36)describestheAs203isolationtowerasfollows; asec-
tionofthe"poisontower,"wherethearseniousacidiscondensedinthespaces
M,N, 0, P,Q, R;thefumesenterthelowercompatmentatL,andthenfollow
the direction ofthe arrows, until finally, the uncondensable vapors depart
throughtheopeningS. Inthefluesandfirstchambersofthetower, thepurest
arsenic is to be found, thatwhich isdeposited in the upperonesbeing im-
pregnatedwithsulfur. Attheterminationoftheworkingofeachcharge, the
covers, T, aretakenaway forthepurposeofcollectingthewholeofthecon-
densedarseniousacidintothelowerchamber, whichisemptiedonlyabout
onceevery2monthsandcontainsatthatperiodabout25 tonsoftheimpure
compound. Thearsenious acidprocuredbythe foregoing modeispurified
by sublimation before it is sent to market.
to theageof30 or 35 years. Knowing thedeleterious natureof
theiroccupation, they arecareless" (29).
Obviously, as industrialhygieneincreased, a waveofcancer
deaths occurred (4) andthen abated ashygieneimproved even
further and as usage waned in the 1960s forward (30). Thus,
there may be a narrow window betweentoxicity andtolerance
where cancer is evidenced, and this may contribute to the dif-
ficulty of showing a carcinogenic effect in animals. Some
negativerodentcancerbioassay datamay, however, begenuine,
asforAs2S3(31),givenitsinactivityasagenotoxininthepresent
experiments,butthecarcinogenicinactivityofarsenitetorodents
ismoremysterious(4). Afurthercontributiontotheproblemof
demonstratinganeffectinanimalsmaybestatisticalandrelated
to the heterogeneous effects seen for skin cancers induced by
arsenite(asFowler'ssolution)inman.Thus,theusualdoseofO.2
to 0.5 mL ofa 1% solution gives rise to skin cancers inonly a
susceptiblesubgroupofhumans(4). Cuzicketal.(32)reported
nooverallincreasein(internal)cancerincidenceamongacohort
ofpatientstreatedorallywithFowler'ssolution( 1.2mg/kg/day
for9months), butanincreaseinskincancer was seenamong a
subgroup showing signs of arsenical poisoning and derma-
tologicalchangessuchashyperkeratosis. Itwouldobviouslybe
ofgreatvaluetoresolvethecarcinogenicityofarsenictrioxideor
sodium/potassiumarsenitetorodentsbytheconductofafullNa-
tional Toxicology Program-type rodent bioassay. To date, the
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onlyderivativeofarsenictestedbytheNationalToxicologyPro-
gramisroxarsone(anitrophenylarsonicacid),andthatgaveon-
lyequivocalevidenceofpancreaticcancerinthemalerat(33).
Confirmationofactivityforarseniteinthemousebonemarrow
micronucleusassay,coupledtothedemonstrationbyArrouijalet
al. (26)ofsimiliaractivityforNi3S2andourrecentobservation
ofactivityinthisassayfortwofurtherhumancarcinogens[sulfur
mustard (34) andN-(2-chloroethyl)-N-(4-methylcyclohexyl)-N-
nitrosourea (35)] brings the number of human carcinogens
clastogenictotherodentbonemarrowto23(2).
H. T. acknowledges financial support by the Laboratory oftheGovernment
Chemist.
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